Roche presents data from a mock clinical trial study suggesting that
next-generation discovery proteomics is ready for use in clinical trials.
PALM SPRINGS, Calif. & SCHLIEREN, Switzerland–(BUSINESS WIRE)–lt;a href=”https://twitter.com/hashtag/MSACL?src=hash” target=”_blank”gt;#MSACLlt;/agt;–Clinical researchers may soon be able to directly measure and quantify
thousands of proteins from patient tissues in clinical trials using
next-generation label-free proteomics technology developed by Biognosys,
a Swiss proteomics company.
This was suggested by a presentation of a collaborative study led by Dr.
Axel Ducret (F. Hoffmann-La Roche Ltd) at the MSACL 2019 conference
(Mass Spectrometry Applications to the Clinical Lab) in Palm Springs.
Biognosys contributed data to a mock study that mimicked implementation
of discovery proteomics in a clinical investigation framework. The 30
FFPE colorectal cancer (CRC) tumor specimen data set was representative
of samples obtained in clinical trials. The data was investigated using
both a targeted and a discovery proteomic strategy.
The data provided by Biognosys was generated using the next-generation
data-independent acquisition technology; a label free mass spectrometric
method that combines parallel acquisition of peptide signatures with
targeted data analysis. Identification of proteins is based on large
libraries of high-quality reference peptide spectra, which allow for
precise relative quantification.
Direct protein expression data provides an important complement to
transcriptome analysis, which is often used as a proxy for global
protein expression. In this study, close to 9,000 proteins were
identified with median technical %CVs well below 10%, providing
sufficient statistical power to detect subtle changes in protein
expression that may occur in tumor tissue.
Dr. Claudia Escher, COO at Biognosys says: “We work with many of the
most innovative pharma and biotech companies, who use our discovery
proteomics services to advance their early-stage research programs. We
increasingly see an interest in using our technology further into the
clinical trial phase. We are excited about the perspective that
discovery proteomics can soon be an integrated part in clinical trials,
and Biognosys is dedicated to bring it to the market”.
This study lays the foundation for a discovery proteomics pipeline that
can be operated and documented according to GCP guidelines, and applied
to support the design of more effective and efficient clinical trials.
About Biognosys
Biognosys is a leader in next-generation proteomics, dedicated to
transforming life science research by making the most advanced
proteomics tools available to researchers. The company offers a suite of
products and services to decode the proteome and equip researchers from
all fields with a deep view of protein expression in cells, tissues, or
body fluids. Biognosys’ technology is based on high-resolution mass
spectrometry, combined with a novel parallel signal processing approach,
for unprecedented quantification of large proteomes in a single
experiment. More information at: www.biognosys.com
Contacts
Oliver Rinner, PhD
+41 78 (0) 664 47 11
oliver.rinner@biognosys.com